📇 Rhumatologue ·
Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
1 raison identifiée
Praticien-chercheur
7 articles scientifiques publiés — formation continue solide
✨ Génération du profil synthétique IA en cours…
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Archives de pediatrie : organe officiel de la Societe francaise de pediatrie · 1994
Intensive care medicine · 1995
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025
Abstract Background Despite tuberculosis being a well-known concern in patients with advanced human immunodeficiency virus (HIV), the STATIS trial, which focused on its management, highlighted significant mortality rates. Histoplasmosis, a fungal disease endemic in sub-Saharan Africa, presents with similar clinical manifestations as tuberculosis. Therefore, it may be prevalent and potentially responsible for deaths in patients with advanced HIV in this region. We conducted an ancillary study of the ANRS STATIS trial to provide the first prevalence estimates of histoplasmosis among individuals with advanced HIV in Côte d'Ivoire. Methods We analyzed urine samples from patients previously enrolled in the STATIS trial in Côte d’Ivoire. These ambulatory patients with newly diagnosed HIV infection, CD4+ T-cell counts <100/µL, and eligible for antiretroviral therapy (ART) were randomized to receive either systematic or test-guided tuberculosis treatment. We performed Histoplasma antigen enzyme immunoassay on their urine samples. Results The prevalence of Histoplasma antigenuria was 68/280 (24.3%; 95% CI: 19.5%–29.8%), including 52/280 (18.6%; 95% CI: 14.3%–23.7%) symptomatic patients. Of 22 tuberculosis cases documented at inclusion, 8 (36.4%) also had Histoplasma antigenuria. In patients who died within the 48-week follow-up, the prevalence of Histoplasma antigenuria was 15/42 (35.7%% 95% CI: 22.0%–52.0%) compared with 22.3% (95% CI: 17.3%–28.2%) in those surviving. These survivors had a higher body mass index, CD4+ T-cell count, and hemoglobin and platelet count than those who died. Conclusions The prevalence of Histoplasma antigenuria was comparable to that of tuberculosis, and histoplasmosis was potentially responsible for preventable deaths. Prospective studies are needed to confirm these findings and promote screening strategies in sub-Saharan Africa.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
The American journal of tropical medicine and hygiene · 2026 · Case Reports
Henry K, Françoise U, Durand C, Salloum C, et al.
The Pan African medical journal · 2014 · Journal Article
Philippe CM, Bienvenu YA, Francoise MK, Eric MS, et al.
Intensive care medicine · 1995 · Clinical Trial
Dupuy PM, Lançon JP, Françoise M, Frostell CG
Archives de pediatrie : organe officiel de la Societe francaise de pediatrie · 1994 · Case Reports
Berger C, Françoise M, Durand C, Sandre D, et al.
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2026 · Journal Article
Françoise U, Nacher M, Donald SM, Van Eer M, et al.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025 · Journal Article
Sturny-Leclère A, Françoise U, Badjé AD, Garcia-Hermoso D, et al.
PLoS neglected tropical diseases · 2025 · Journal Article
Bourne-Watrin M, Françoise U, Baron SA, Adenis AA, et al.